Fresenius Medical Care: Patient Outcomes Are the Growth Engine, Time to Buy on a Mid-Range Pullback
Fresenius Medical Care (FMS) sits on a cheap trailing valuation (P/E ~12.7, P/B ~0.85) while technicals show bullish momentum and the short-interest picture suggests elevated attention. As payors and health systems increasingly reward better dialysis outcomes, Fresenius' scale in both Care Delivery and Care Enablement positions it to convert clinic…